Orchid Pharma Limited is a vertically integrated pharmaceutical company with capabilities in research, manufacturing, and marketing across multiple therapeutic areas, primarily focusing on antibiotics and anti-infectives.

The company is experiencing pressure in the antibiotic market, particularly with cephalosporin class products, due to declining global demand and aggressive pricing, affecting revenue and profitability.

Orchid recently acquired global rights to Enmetazobactam and the Exblifep trademark following Allecra's insolvency, aiming to out-license this innovative antibiotic globally to drive future revenue.

The company is progressing with strategic projects, including the 7ACA and Cefiderocol projects, which are expected to strengthen its API manufacturing base and reduce import dependency.

Orchid is facing ongoing market challenges, with weak antibiotic demand impacting sales, but it is focused on strategic licensing, cost management, and project execution to navigate the downturn.